Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

BACKGROUND: Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional status outcomes among patients who switch to oral medications from injectable MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuchiner, Tamela, Lucas, Lindsay, Baraban, Elizabeth, Spinelli, Kateri J., Chen, Chiayi, Smith, Alden, Hashemi, Lobat, Cohan, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716591/
https://www.ncbi.nlm.nih.gov/pubmed/33272224
http://dx.doi.org/10.1186/s12883-020-02016-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716591/
https://www.ncbi.nlm.nih.gov/pubmed/33272224
http://dx.doi.org/10.1186/s12883-020-02016-4

Ejemplares similares